Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Current Molecular Medicine|July 19, 2012
Inhibiting HSP90 to treat cancer: a strategy in evolutionL Whitesell, S Santagata, N U Lin
ESMO Open|September 5, 2021
How we treat HER2-positive brain metastasesE Stavrou, E P Winer, N U Lin
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 2, 2012
Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?I Vaz-Luis, E P Winer, N U Lin
The Journal of Clinical Endocrinology and Metabolism|July 1, 1996
A novel mutation in the deoxyribonucleic acid-binding domain of the vitamin D receptor causes hereditary 1,25-dihydroxyvitamin D-resistant ricketsN U Lin, P J Malloy, N Sakati, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 7, 2013
Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumabE M Olson, M Abdel-Rasoul, J Maly, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2011
Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancerE M Olson, N U Lin, P J DiPiro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2014
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIAI E Krop, N U Lin, K Blackwell, et al.
Oncogene|October 27, 2015
PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancersQ Wang, P Liu, J M Spangle, et al.
ESMO Open|June 18, 2025
Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancerP Tarantino, D Lee, J Foldi, et al.
Breast Cancer Research and Treatment|May 7, 2013
A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancerN U Lin, D S Seah, R Gelman, et al.
Pageof 3